Drug Approval | December 16, 2025
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Subscribe To Our Newsletter & Stay Updated
